Colonoscopy

EQS-News: Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance

Retrieved on: 
Saturday, September 16, 2023
Biopsy, CRC, Clinical trial, Cancer, Polyp, Gene expression, Biomarker, Specificity, Messenger, Colon, Conditional sentence, Publishing, Rectum, Data, Patient, Collection, Colorectal cancer, Colonoscopy, Ageing, AA, Vaccine, Medical imaging

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance

Key Points: 
  • Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
    BERKELEY, US – MAINZ, Germany – September 13, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today positive topline results from its ColoFuture study.
  • The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%.
  • COLOFUTURE is an international clinical study evaluating the performance of the Mainz Biomed Colorectal Cancer Screening Test.

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

Retrieved on: 
Wednesday, September 13, 2023
Biopsy, CRC, Clinical trial, Cancer, Polyp, Gene expression, Biomarker, Messenger, Colon, Conditional sentence, Publishing, Rectum, Data, Patient, Collection, Colorectal cancer, Colonoscopy, Ageing, AA, Medical imaging

BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today positive topline results from its ColoFuture study. The ColoFuture study is a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert®, the Company’s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) which is being commercialized across Europe and in select international territories. The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%.

Key Points: 
  • The results of this groundbreaking study included sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%.
  • COLOFUTURE is an international clinical study evaluating the performance of the Mainz Biomed Colorectal Cancer Screening Test.
  • The primary endpoints of the study are to determine sensitivity and specificity for colorectal adenocarcinoma.
  • There are multiple secondary and exploratory endpoints including determining sensitivity and specificity for advanced precancerous lesions in the colon.

Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

Retrieved on: 
Tuesday, August 22, 2023
Polish Center for Holocaust Research, The New England Journal of Medicine, Partnership, CRC, Cancer, Research, World Cancer Research Fund International, Collection, Risk, Colorectal cancer, Colonoscopy, Accreditation, Mortality, Ageing, Pharmaceutical industry

BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp.
  • The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”).
  • As an accredited research laboratory sanctioned by the Polish Center for Accreditation, the laboratory is headquartered in Katowice, Poland, and boasts an expansive network of over 300 collection points throughout the country.
  • Together, we are well positioned to help transform and improve the current cancer screening options in Poland and provide timely interventions that have the potential to save lives."

EQS-News: Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

Retrieved on: 
Tuesday, August 22, 2023
Polish Center for Holocaust Research, The New England Journal of Medicine, Partnership, CRC, Cancer, Research, World Cancer Research Fund International, Collection, Risk, Colorectal cancer, Colonoscopy, Accreditation, Mortality, Ageing, Pharmaceutical industry

The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”).

Key Points: 
  • The partnership marks another significant step forward in providing new and innovative testing options to underserved populations in the battle against colorectal cancer (“CRC”).
  • As an accredited research laboratory sanctioned by the Polish Center for Accreditation, the laboratory is headquartered in Katowice, Poland, and boasts an expansive network of over 300 collection points throughout the country.
  • With a comprehensive portfolio, testDNA is renowned for delivering state-of-the-art genetic-based testing solutions tailored to individual needs.
  • Together, we are well positioned to help transform and improve the current cancer screening options in Poland and provide timely interventions that have the potential to save lives."

Kips Bay Endoscopy Center Now Incorporates Artificial Intelligence System for Enhanced Colonoscopy Screenings in New York City

Retrieved on: 
Thursday, August 17, 2023
Managed Care, Software, Other Health, Robotics, Data Management, Oncology, Technology, Medical Devices, Hospitals, Artificial Intelligence, Biotechnology, Other Technology, Health, Polyp (medicine), Surgeon, Statistics, Cancer, KBEC, Esophagus, Intelligence, Large intestine, Endoscopy, Colon, Stomach, Adenoma, Patient, Physician, Risk, Colorectal cancer, Gastroenterology, Colonoscopy, Artificial intelligence, AI, GI, Death, Polyp, Medical device, Medical imaging

Kips Bay Endoscopy Center (KBEC), a Covenant Physician Partner , will offer patients receiving a colonoscopy an enhanced screening with the aid of GI Genius™ intelligent endoscopy module.

Key Points: 
  • Kips Bay Endoscopy Center (KBEC), a Covenant Physician Partner , will offer patients receiving a colonoscopy an enhanced screening with the aid of GI Genius™ intelligent endoscopy module.
  • The GI Genius™ module employs artificial intelligence (AI) to help physicians detect polyps—a powerful new ally in the fight against colorectal cancer.
  • “We are the only privately-owned and fully independent surgery center offering artificial intelligence assisted colonoscopies in Midtown Manhattan,” added Ms. Yuen.
  • New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection.

Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System

Retrieved on: 
Thursday, August 10, 2023
VHA, Bleeding, CRC, Gastrointestinal tract, Veterans Health Administration, EVS, Eve Systems, Endoscopy, Ministry, Literature, Patient, Risk, Blood, Colonoscopy, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Nursing, Birth control, Health

“We are pleased to secure regulatory clearance for the Pure-Vu EVS System in Israel, which is considered an advanced medical system globally and one of the largest markets in this region.

Key Points: 
  • “We are pleased to secure regulatory clearance for the Pure-Vu EVS System in Israel, which is considered an advanced medical system globally and one of the largest markets in this region.
  • Leading healthcare systems in a number of regions in the U.S. and the Veterans Health Administration (VHA) are currently utilizing the Pure-Vu EVS System.
  • The Pure-Vu System EVS integrates with standard and slim colonoscopes, to improve visualization during colonoscopy while preserving established procedural workflow and techniques.
  • The Pure-Vu EVS is already cleared by the U.S. Food and Drug Administration (FDA) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy.

United Digestive Announces Artificial Intelligence System for Enhanced Colonoscopy Screenings

Retrieved on: 
Tuesday, August 8, 2023
Colonoscopy, UD, Colorectal cancer, AI, Endoscopy, Health, GI, Patient, Polyp, Mobile phone, Nursing, Medical imaging

ATLANTA, Aug. 8, 2023 /PRNewswire/ -- United Digestive now offers patients receiving a colonoscopy an enhanced screening by GI Genius™ intelligent endoscopy module. The GI Genius™ module uses advanced AI software to highlight suspicious polyps with a visual marker in real-time—serving as the gastroenterologist's ever-vigilant second observer. It is a powerful new ally in the fight against colorectal cancer.

Key Points: 
  • ATLANTA, Aug. 8, 2023 /PRNewswire/ -- United Digestive now offers patients receiving a colonoscopy an enhanced screening by GI Genius™ intelligent endoscopy module.
  • The GI Genius™ module uses advanced AI software to highlight suspicious polyps with a visual marker in real-time—serving as the gastroenterologist's ever-vigilant second observer.
  • United Digestive is committed to investing in new technologies that improve patient outcomes.
  • According to Dr. John Suh, Chief Medical Officer of United Digestive, "GI Genius™ is a game-changer in the field of colonoscopy screenings.

Independence Blue Cross and The Colorectal Cancer Alliance Launch 45+ Reasons Campaign to Support Colorectal Cancer Prevention

Retrieved on: 
Tuesday, August 8, 2023
Survival rate, Independence Blue Cross, Perelman School of Medicine at the University of Pennsylvania, Partnership, University, Wellness, Health equity, Cancer, Large intestine, African Americans, Colorectal Cancer Alliance, Penn Medicine Rittenhouse, Black, Organization, Perelman Center for Advanced Medicine, Community Alliance, Incidence, Colorectal cancer, Development, MD, Pennsylvania Department of Aging, Risk, Salix Pharmaceuticals, Child, Colonoscopy, Cycle, Diversity, Radio, University of Pennsylvania Health System, Mortality, American Cancer Society, USPSTF, Willow, Pennsylvania Department of Health, Social media, Disease, Pharmaceutical industry, Mobile phone, Vaccine, Independence, Medicine

PHILADELPHIA, Aug. 8, 2023 /PRNewswire/ -- Independence Blue Cross (Independence) and the Colorectal Cancer Alliance (the Alliance) announced the launch of 45+ Reasons, a campaign to get more than 5,000 Black Philadelphians ages 45-75 screened for colorectal cancer to reduce the significantly higher incidence and mortality rates of Black Americans. The campaign supports the Cycles of Impact initiative launched by Independence and the Alliance in 2022.

Key Points: 
  • To ensure that the colorectal cancer prevention and screening messages reach those most at risk, the Alliance is launching a compelling new awareness campaign called 45+ Reasons.
  • The community engagement, social media, and advertising campaign aims to instill much-needed trust in the healthcare system with fact-based support for colorectal cancer as a preventable cancer.
  • One way we are addressing this is through this partnership with the Colorectal Cancer Alliance to reduce gaps in colorectal cancer screening rates among Black Philadelphians, who are disproportionately impacted by colorectal cancer."
  • "As the largest nonprofit organization solely committed to ending colorectal cancer, the Alliance is uniquely positioned to lead this bold health intervention," said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

CellMax Life Appoints Dr. Ross D. "Rusty" Segan to Advisory Board

Retrieved on: 
Wednesday, August 2, 2023
Minimally invasive procedure, University, CRC, Gastroenterology, Cancer, Tripler Army Medical Center, Olympus Corporation, Medicine, Science, Medtronic, University of Maryland Medical Center, United States Department of the Army, Adenoma, Colonoscopy, Johnson & Johnson, Injury, Vaccine, Medical device

SUNNYVALE, Calif., Aug. 2, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer (CRC) screening blood test, that also detects pre-cancerous polyps, or adenomas, today announced the appointment of Dr. Ross D. Segan as an advisory board member.

Key Points: 
  • CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer (CRC) screening blood test, that also detects pre-cancerous polyps, or adenomas, today announced the appointment of Dr. Ross D. Segan as an advisory board member.
  • SUNNYVALE, Calif., Aug. 2, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer (CRC) screening blood test, that also detects pre-cancerous polyps, or adenomas, today announced the appointment of Dr. Ross D. Segan as an advisory board member.
  • "Rusty is a visionary in aligning science, medicine and technology, bringing innovations that are clinically relevant into real-life healthcare settings," said Atul Sharan, CEO of CellMax Life.
  • For more information about CellMax Life and its FirstSight test, visit cellmaxlife.com .

Statement from the Prevent Cancer Foundation on updated guidance for colorectal cancer screening from the American College of Physicians

Retrieved on: 
Monday, July 31, 2023
Bleeding, Prevent Cancer Foundation, National Colon Cancer Awareness Month, Fear, Cancer, Large intestine, Risk, Perforated ulcer, Organization, Incidence, Colorectal cancer, National Cancer Institute, Patient, American College of Gastroenterology, Colonoscopy, Confusion, Mortality, American Cancer Society, Transport, American College, NCI, American College of Physicians, ACP, USPSTF, Dietary supplement, Medical imaging, Dairy

Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.

Key Points: 
  • Alexandria, Va., July 31, 2023 (GLOBE NEWSWIRE) -- The American College of Physicians (ACP) today issued updated guidance for colorectal cancer screening, recommending asymptomatic, average-risk adults should begin screening for colorectal cancer at age 50.
  • The Prevent Cancer Foundation strongly opposes the updated guidance, which goes against the latest evidence-based screening recommendations from the organizations working in the cancer screening space every day.
  • The Prevent Cancer Foundation supports following the guidelines of the USPSTF, the American Cancer Society and American College of Gastroenterology and encourages all adults of average risk to begin colorectal cancer screening at age 45.
  • There are several options available for colorectal cancer screening, and all available colorectal cancer screening methods are safe and can save lives.